CDK12 and neoplasm: In contrast, tumor mutation burden, microsatellite instability (MSI) status, and genomic alterations in select DNA repair genes, Cyclin Dependent Kinase 12 (CDK12), and in Androgen receptor (AR), which are the genomic features that could influence the clinical decisions, were found not to differ significantly between the two groups studied.